👀 Copy Legendary Investors' Portfolios in One ClickCopy For Free

LivePerson Analysts Hug The Sidelines On Q4 Print, Lower Outlook

Published 16/03/2023, 16:17
© Shutterstock LivePerson Analysts Hug The Sidelines On Q4 Print, Lower Outlook
LPSN
-

Benzinga - Shares of LivePerson Inc (NASDAQ: LPSN) crashed in early trading on Thursday, after the company reported its fourth-quarter results.

  • Needham analyst Ryan MacDonald maintained a Hold rating on the stock.
  • KeyBanc Capital Markets analyst Thomas Blakey downgraded the rating from Overweight to Sector Weight.
Check out other analyst stock ratings.

Needham

  • The company missed the consensus estimates “due to an inability to recognize rev. for a Medicare reimbursement program for its Wild Health offering,” MacDonald said in a note.
  • “While we view this as a bit of misfortune, LPSN's lower outlook for FY23 was intentional as they refocus the business on the B2B Core & Wild Health,” the analyst wrote. “As a result, LPSN is removing ~$70mm of non-core/non-recurring rev. in an effort to drive more profitable growth."
  • Although this is the right strategy, there is significant uncertainty “as the core business is being impacted by the macro & Wild Health is in the early innings,” MacDonald stated.
KeyBanc
  • LivePerson delayed its 10K “due to revenue adjustments tied to suspended Medicare reimbursements related to a now-discontinued program,” Blakey said in the downgrade note.
  • Additionally, LivePerson cut 2023 revenue outlook by ~22% after citing ~14% of revenue as non-core with additional pressures from macro including smaller deals,” he added.
  • “We continue to believe LivePerson is well positioned to benefit from secular emerging trends in digital engagement and AI, with the latter benefiting from the Company’s unique data sets to enhance AI outcomes, but new growth and margin frameworks for the total company as well as increased execution risks, in our view, inform our downgrade of shares,” the analyst wrote.
LPSN Price Action: Shares of LivePerson declined by 54.25% to $4.47 at the time of publication Thursday.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.